Revenue from Vaxini was pressured by lower average selling prices linked to higher rebates and 340B discounts; these pricing headwinds are expected to persist in the near term according to management ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: BAQSIMI ® sales decreased primarily due to a lower average selling price, as a result of a change ...

Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset ...

Please provide your email address to receive an email when new articles are posted on . Risk for first moderate/severe COPD exacerbation was lower among dry powder vs. metered-dose or soft mist ...

I started voice lessons last May in an effort to stop blowing my voice out every time I belted Creed’s “One Last Breath” at karaoke. I’ve made strides since then — moving on from Scott Stapp to David ...

Amphastar Pharmaceuticals is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit ...

Management explicitly guided to lower gross margins in 2026, attributing the pressure to "continued pricing pressure on glucagon, epinephrine, and phytonadione, which are high-margin products," and ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...